Exploratory Study of Mavacamten (MYK-461) in Patients with Symptomatic Non-obstructive Hypertrophic Cardiomyopathy (nHCM) and Preserved Left Ventricular Ejection Fraction
Brief description of study
The purpose of this study is to compare the effect of the investigational drug, mavacamten, (MYK-461), to a placebo (an inactive substance) in patients with Non-obstructive Hypertrophic Cardiomyopathy (nHCM).
Detailed description of study
This study is being done to test whether mavacamten is safe, and can be tolerated in nHCM and to study whether it helps to improve symptoms or ability to exercise.
Mavacamten is an investigational drug. This means that it has not been approved by the Food and Drug Administration (FDA) or any regulatory agency for routine clinical use, including the treatment of nHCM.
Mavacamten is an investigational drug. This means that it has not been approved by the Food and Drug Administration (FDA) or any regulatory agency for routine clinical use, including the treatment of nHCM.
If you decide you want to participate in the study, you will be asked to come into the clinic for a screening visit. You will undergo tests and procedures to help the study doctor decide if you qualify to take part in this study. If you qualify for the study, you will visit the clinic according to a schedule.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
cardiomyopathy,nHCM
-
Age: Between 18 Years - 99 Years
-
Gender: All
Updated on
24 Jul 2023.
Study ID: 829315
